Viking Therapeutics (VKTX) stock jumped 6% out of the gate Monday, but was last seen notably lower. The volatility comes after the biopharmaceutical company reported positive new clinical data for its weight-loss pill, VK2735.
The data released by Viking showed that adults taking the highest dosage of the oral VK2735 tablet lost an average of 8.2% of their body weight in just four weeks, or 6.8% more than those that received a placebo.
"We believe the VENTURE data demonstrate VK2735's promising efficacy and tolerability profile through 13 weeks of weekly dosing and support our belief that less frequent dosing regimens may provide effective maintenance of weight control," said Viking CEO Brian Lian, Ph.D., in a statement.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"The updated oral Phase 1 study results continue to demonstrate an encouraging tolerability profile and promising signs of clinical activity at doses of up to 100 milligrams daily," the executive added. "We believe the durable effects observed following 28 days of dosing suggest potential opportunities to introduce lower dose regimens following an initial induction of weight loss."
Lian noted that Viking plans to move forward on the clinical path with the Food and Drug Administration (FDA) later this year for an injectable version of VK2735 and that they expect to initiate a Phase 2 study of the oral tablet formation by the end of the fourth quarter.
Is Viking Therapeutics stock a buy, sell or hold?
It's been a volatile year for Viking Therapeutics stock, though good news on the weight-loss-drug front has the healthcare stock up 260% since the start of January. And Wall Street sees even more upside for VKTX.
According to S&P Global Market Intelligence, the consensus analyst target price for the mid-cap stock is $112.85, representing implied upside of nearly 55% to current levels. Additionally, the consensus recommendation is Strong Buy.
Financial services firm William Blair has an Outperform rating (equivalent to a Buy) on VKTX and gives it a current fair value of $96 per share.
"From a competitive advantage perspective, VK2735's status as a Phase III-ready asset, coupled with the ability to formulate into an oral route of administration (tablet formulation), along with an amylin program that is on track to enter Phase I development next year, offers a unique set of attractive characteristics in the lens of big pharma," says William Blair analyst Andy Hsieh.
The analyst acknowledges that it is "risky to base our investment thesis on an eventual takeout, the prospect is reasonably high given Viking's clinical differentiation, combined with the large total addressable market of chronic metabolic conditions."
Related content
-
Common Holiday Scams to Watch For This Holiday SeasonProtect your wallet and peace of mind with these essential tips on how to avoid holiday scams.
-
Disney Hikes Its Dividend: What This Means for InvestorsDisney announced late Wednesday that it's raising its dividend by 33%. Here's what you need to know.
-
Disney Hikes Its Dividend: What This Means for Investors
Disney announced late Wednesday that it's raising its dividend by 33%. Here's what you need to know.
-
Roth or Traditional: How to Choose a Retirement Tax StrategyWhen picking which type of 401(k) or IRA is right for you, consider whether you want to save a little on your taxes now — or save a lot more on them later.
-
Buying an Annuity? Avoid These Three Classic MistakesAnnuities can be a sensible option for retirement, offering steady income in your later years. But these common traps can damage your investment.
-
Stock Market Today: Stocks Rally as Econ News Affirms Rate-Cut BetsSome soft economic data was good news for rate cuts and risk assets.
-
Why Pure Storage Stock Is Sailing Higher After EarningsPure Storage stock is surging after the data storage firm beat earnings expectations and announced a deal with a major technology company. Here's what you need to know.
-
Is Dollar Tree Stock a Buy, Hold or Sell After Earnings?Dollar Tree stock is higher Wednesday after the retailer beat Q3 earnings expectations and updated its full-year outlook. Here's what Wall Street has to say.
-
UnitedHealth Cancels Investor Day After Executive Brian Thompson Is ShotUnitedHealth Group was scheduled to host its annual Investor Day Wednesday but the event was cancelled following the fatal shooting of its insurance unit CEO.
-
Salesforce Leads Dow Jones Stocks After Earnings. Here's WhySalesforce stock is soaring after the tech giant beat revenue expectations for its fiscal third quarter and gave a strong outlook for its fourth quarter.
